ALTACE

This brand name is authorized in Canada, United States

Active ingredients

The drug ALTACE contains one active pharmaceutical ingredient (API):

1 Ramipril UNII L35JN3I7SJ - RAMIPRIL

Ramiprilat, the active metabolite of the prodrug ramipril, inhibits the enzyme dipeptidylcarboxypeptidase I (synonyms: angiotensin-converting enzyme; kininase II). In plasma and tissue this enzyme catalyses the conversion of angiotensin I to the active vasoconstrictor substance angiotensin II, as well as the breakdown of the active vasodilator bradykinin. Reduced angiotensin II formation and inhibition of bradykinin breakdown lead to vasodilatation. Read about Ramipril

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ALTACE Capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09AA05	Ramipril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02221829, 02221837, 02221845, 02221853, 02281112
Country: US	FDA, National Drug Code	Identifier(s): 61570-110, 61570-111, 61570-112, 61570-120